Janku F, Kim TM, Iyer G, Spreafico A, et al. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur J Cancer 2024;196:113458.
PMID: 38039779